Clinical Trial Update: Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of oral treprostinil for calcinosis in patients with systemic sclerosis has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Calcinosis
• Systemic Sclerosis

Drugs mentioned

• Treprostinil (treprostinil)

Snippet

Sponsor: Stanford University | Conditions: Systemic Sclerosis, Calcinosis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-10